Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT02961101
PHASE1/PHASE2

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Sponsor: Han weidong

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the feasibility, safety, and efficacy of anti-PD-1 antibody alone or in combination with low-dose decitabine in patients with relapsed or refractory malignancies, including Non-Hodgkin'lymphoma, Hodgkin'lymphoma, gastrointestinal cancers, hepatocellular carcinoma, breast cancer, ovarian cancer or lung cancer or renal-cell cancer or pancreatic cancer or bile duct cancer.

Official title: Anti-PD-1 Antibody Alone or in Combination With Low-dose Decitabine and/or Chemotherapy in Relapsed or Refractory Malignancies: an Open-label Phase I/II Trial

Key Details

Gender

All

Age Range

12 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

250

Start Date

2016-05

Completion Date

2026-05

Last Updated

2026-01-22

Healthy Volunteers

No

Interventions

DRUG

Anti-PD-1 antibody

Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks

DRUG

Decitabine

Decitabine will be given at 10mg/d on day 1to 5 by IV every three weeks

DRUG

Chemotherapy

Chemotherapy be given depends on the cancer type and treatment regimen before enrollment.

Locations (1)

Biotherapeutic Department of Chinese PLA General Hospital

Beijing, Beijing Municipality, China